An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Clinical trial NCT00932893 · COMPLETED

Trial details

NCT number: NCT00932893
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2009-09-01
Primary completion: 2012-03-01
Enrollment: 347

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.